📗 Cite This Artifact
neuroinflammation-ad-pd-als
neuroinflammation-ad-pd-als
Overview
Neuroinflammation Across Ad, Pd, And Als plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Neuroinflammation is a hallmark feature shared across Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). While each disease has distinct clinical and pathological features, chronic activation of the innate immune system in the brain—primarily driven by microglia and astrocytes—contributes to neuronal dysfunction and death in all three conditions. This integration page synthesizes the common and disease-specific inflammatory pathways that link these major neurodegenerative disorders[@griciuc2018].
The inflammatory response in neurodegeneration is characterized by elevated pro-inflammatory cytokines, reactive oxygen species (ROS) production, [complement system](/entities/complement-system) activation, and persistent activation of pattern recognition receptors such as TLRs and NLRs. Understanding these shared inflammatory mechanisms provides opportunities for therapeutic interventions that may benefit multiple neurodegenerative conditions[@griciuc2013].
Common Inflammatory Mechanisms
Microglial Activation
...
neuroinflammation-ad-pd-als
Overview
Neuroinflammation Across Ad, Pd, And Als plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Neuroinflammation is a hallmark feature shared across Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). While each disease has distinct clinical and pathological features, chronic activation of the innate immune system in the brain—primarily driven by microglia and astrocytes—contributes to neuronal dysfunction and death in all three conditions. This integration page synthesizes the common and disease-specific inflammatory pathways that link these major neurodegenerative disorders[@griciuc2018].
The inflammatory response in neurodegeneration is characterized by elevated pro-inflammatory cytokines, reactive oxygen species (ROS) production, [complement system](/entities/complement-system) activation, and persistent activation of pattern recognition receptors such as TLRs and NLRs. Understanding these shared inflammatory mechanisms provides opportunities for therapeutic interventions that may benefit multiple neurodegenerative conditions[@griciuc2013].
Common Inflammatory Mechanisms
Microglial Activation
[Microglia](/cell-types/microglia-neuroinflammation) are the resident immune cells of the central nervous system and serve as the first line of defense against pathogens and cellular debris. In neurodegenerative diseases, chronic microglial activation—often termed "microglial priming"—creates a self-perpetuating cycle of inflammation[@heneka2017]. [@liddelow2017]
Key microglial pathways activated in neurodegeneration include: [@swanson2019]
- [TREM2](/proteins/trem2) signaling: Triggering receptor expressed on myeloid cells 2 (TREM2) is a receptor on microglia that recognizes [amyloid-beta](/proteins/amyloid-beta), apoptotic cells, and lipidated proteins. TREM2 variants significantly increase AD risk, while its role in PD and ALS is actively investigated[@griciuc2018].
- CD33 interaction: The CD33 receptor modulates microglial phagocytosis, and genetic variants affecting CD33 function influence AD susceptibility[@griciuc2013].
- CR3 complement receptor: Complement receptor 3 (CR3, also known as CD11b/CD18) mediates microglial phagocytosis of complement-opsonized targets.
Astrocyte Reactivity
[Astrocytes](/entities/astrocytes) adopt reactive phenotypes in response to neuroinflammation, transitioning from their homeostatic functions to inflammatory states. Reactive astrocytes produce cytokines, chemokines, and complement proteins that can both protect and harm [neurons](/entities/neurons)[@liddelow2017].
In AD, reactive astrocytes cluster around amyloid plaques and may both limit plaque spread and contribute to neuronal dysfunction. In PD, astrocyte reactivity surrounds dopaminergic neurons in the substantia nigra, and astrocytic dysfunction may contribute to [alpha-synuclein](/proteins/alpha-synuclein) propagation. In ALS, astrocytes fail to support motor neurons and release toxic inflammatory mediators.
The NLRP3 Inflammasome
The [NLRP3](/entities/nlrp3-inflammasome) (NLR family pyrin domain containing 3) inflammasome is a cytosolic protein complex that activates caspase-1, leading to maturation and release of pro-inflammatory cytokines IL-1β and IL-18. The NLRP3 inflammasome is activated by various neurodegeneration-associated signals including amyloid-beta fibrils, alpha-synuclein oligomers, and mitochondrial [ROS](/entities/reactive-oxygen-species)[@swanson2019].
Disease-Specific Inflammatory Mechanisms
Alzheimer's Disease
In AD, neuroinflammation is driven primarily by amyloid-beta plaques and [tau](/proteins/tau) pathology. Microglial cells surround plaques in an attempt to clear amyloid, but chronic activation leads to a pro-inflammatory state that exacerbates tau pathology and synaptic loss.
Key inflammatory mechanisms in AD include:
- Aβ-induced microglial activation: Amyloid-beta directly activates microglia through TLR2, [TLR4](/entities/tlr4), and CD14 receptors, triggering [NF-κB](/entities/nf-kb) signaling and cytokine production.
- TREM2 loss-of-function: Risk variants in TREM2 impair microglial response to amyloid, reducing plaque clearance and promoting inflammation.
- Complement-mediated synapse loss: Early complement activation (C1q, C3) leads to synaptic pruning that correlates with cognitive decline.
- Microglial epigenetic changes: Long-term inflammation causes epigenetic modifications in microglia that maintain the activated state.
Parkinson's Disease
In PD, neuroinflammation accompanies alpha-synuclein aggregation and dopaminergic neuron loss. The inflammatory response may be both a cause and consequence of alpha-synuclein pathology.
Key inflammatory mechanisms in PD include:
- α-Synuclein-triggered inflammation: Oligomeric and fibrillar alpha-synuclein activates microglia through TLR4 and NLRP3 inflammasome.
- Microglial priming: Prior inflammatory insults sensitize microglia to respond more vigorously to subsequent challenges.
- Peripheral immune involvement: T-cell infiltration into the substantia nigra has been documented in PD patients.
- [Gut-brain axis](/entities/gut-brain-axis) inflammation: Gastrointestinal inflammation may precede and contribute to central nervous system pathology in PD.
Amyotrophic Lateral Sclerosis
ALS features neuroinflammation driven by mutant SOD1, [TDP-43](/mechanisms/tdp-43-proteinopathy), and FUS protein aggregates. Both microglia and astrocytes contribute to motor neuron injury.
Key inflammatory mechanisms in ALS include:
- SOD1 mutations: Mutant SOD1 in astrocytes and microglia triggers inflammatory responses that damage motor neurons.
- TDP-43 pathology: Cytoplasmic TDP-43 aggregates activate the NLRP3 inflammasome and cause mitochondrial dysfunction.
- Astrocyte toxicity: ALS astrocytes release inflammatory mediators that are directly toxic to motor neurons.
- Microglial phenotype switching: Microglia transition from neuroprotective to neurotoxic phenotypes as disease progresses.
Therapeutic Implications
Anti-inflammatory Therapies
Several anti-inflammatory approaches are being explored across AD, PD, and ALS:
- NLRP3 inhibitors: Small molecule inhibitors of NLRP3 (e.g., MCC950) show promise in preclinical models of all three diseases.
- TREM2 agonists: Enhancing TREM2 signaling may improve microglial plaque clearance in AD.
- Minocycline: This tetracycline antibiotic has anti-inflammatory properties and has been trialed in AD, PD, and ALS.
- Natural compounds: Curcumin, epigallocatechin gallate (EGCG), and resveratrol have anti-inflammatory effects in neurodegeneration models.
Immunomodulatory Approaches
Beyond direct anti-inflammatory strategies, immunomodulatory approaches include:
- Vaccination: Active and passive immunization strategies targeting amyloid-beta, alpha-synuclein, and tau are in development.
- Microglial modulation: Targeting microglial survival factors (CSF1R antagonists) or metabolic pathways represents a novel approach.
Cross-Disease Commonalties
| Mechanism | AD | PD | ALS |
|-----------|----|----|-----|
| Microglial activation | +++ | +++ | +++ |
| NLRP3 inflammasome | +++ | +++ | +++ |
| Complement activation | +++ | ++ | +++ |
| Astrocyte reactivity | +++ | +++ | +++ |
| TREM2 involvement | +++ | ++ | + |
| Peripheral immune cell infiltration | + | +++ | +++ |
Legend: +++ = major contributor, ++ = significant, + = moderate
Molecular Mechanisms of Neuroinflammation
Pattern Recognition Receptors
The innate immune system recognizes pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) through pattern recognition receptors (PRRs). In neurodegeneration, key PRR families include:
Toll-like receptors (TLRs)
[TLR4](/entities/tlr4) recognizes amyloid-beta and alpha-synuclein, triggering MyD88-dependent pro-inflammatory signaling. TLR2 detects damaged myelin and cellular debris. TLR signaling induces NF-κB activation and cytokine production, creating a chronic inflammatory environment that exacerbates neuronal dysfunction.
NOD-like receptors (NLRs)
The [NLRP3](/entities/nlrp3-inflammasome) inflammasome is a cytosolic multiprotein complex that activates caspase-1, leading to maturation of pro-inflammatory cytokines IL-1β and IL-18. In neurodegenerative diseases, NLRP3 is activated by:
- Amyloid-beta fibrils in AD
- Alpha-synuclein oligomers in PD
- Mitochondrial ROS in all three diseases
- ATP released from damaged cells
Cytokine Networks
Pro-inflammatory cytokines
- IL-1β: Potent pro-inflammatory cytokine that drives microglial activation, promotes tau pathology in AD, and contributes to dopaminergic neuron loss in PD. IL-1β levels are elevated in cerebrospinal fluid and brain tissue across all three diseases.
- TNF-α: Rapidly acting cytokine that induces apoptosis in neurons, disrupts the blood-brain barrier, and promotes neuroinflammation. TNF-α inhibitors have shown protective effects in preclinical models of AD, PD, and ALS.
- IL-6: Multifunctional cytokine with roles in acute phase response, B cell differentiation, and neuronal survival. IL-6 is elevated in serum and CSF of patients with neurodegenerative diseases.
- IL-10: Counter-regulatory cytokine that suppresses microglial activation and promotes tissue repair. IL-10 deficiency is associated with increased neuroinflammation and neurodegeneration.
- TGF-β: Pleiotropic cytokine that modulates immune responses, promotes astrocyte scar formation, and regulates synaptic plasticity. TGF-β signaling is dysregulated in AD and PD.
Complement System
The complement system plays a dual role in neurodegeneration—providing protection through debris clearance while contributing to synaptic loss and inflammation when overactivated.
Complement activation in AD
Amyloid-beta directly activates the classical complement pathway through C1q binding. This leads to opsonization of synapses and neurons, marking them for phagocytic removal. C1q and C3 are found associated with amyloid plaques, and complement activation correlates with synaptic loss in AD brains.
Complement in PD
Alpha-synuclein activates complement, and complement components are detected in Lewy bodies. The membrane attack complex (MAC) may directly damage dopaminergic neurons. Genetic variants in complement genes influence PD risk.
Complement in ALS
C1q and C3 are upregulated in ALS spinal cord, and complement activation contributes to motor neuron injury. Astrocyte-derived complement may be particularly important in ALS pathogenesis.
Chemokine Signaling
Chemokines direct immune cell migration and influence neuroinflammation:
- CCL2/MCP-1: Attracts monocytes and microglia to sites of injury; elevated in AD, PD, and ALS
- CX3CL1/Fractalkine: Regulates microglial-neuronal communication; CX3CR1 variants affect disease risk
- CCL5/RANTES: Pro-inflammatory chemokine elevated in PD and ALS
- CXCL12/SDF-1: Involved in neuroinflammation and neuronal survival
Cellular Players in Neuroinflammation
Microglial Activation States
Microglia adopt diverse activation states in neurodegeneration, moving beyond the classical M1/M2 dichotomy:
Disease-associated microglia (DAM)
In AD, a distinct population of disease-associated microglia emerges, characterized by upregulation of genes involved in lipid metabolism, phagocytosis, and lysosomal function. DAM formation requires TREM2 signaling and represents an attempt at protective response that becomes dysregulated.
Neurotoxic microglial phenotype
Pro-inflammatory microglia produce ROS, nitrogen species, and cytokines that damage neurons. This phenotype is induced by:
- Aggregated proteins (Aβ, α-syn, TDP-43)
- Mitochondrial dysfunction
- ATP release from damaged cells
- Complement components
Alternatively activated microglia can support neuronal survival through:
- Growth factor production (BDNF, IGF-1)
- Trophic support
- Anti-inflammatory cytokine release
- Phagocytic clearance of debris
Astrocyte Heterogeneity
Astrocytes display remarkable heterogeneity in neurodegenerative diseases:
A1 reactive astrocytes
As described by Liddelow et al., A1 astrocytes are induced by microglial release of IL-1α, TNF, and C1q. These astrocytes lose supportive functions and gain neurotoxic properties, releasing complement components that eliminate synapses.
A2 reactive astrocytes
A2 astrocytes are considered neuroprotective, upregulating genes involved in tissue repair, glycogen metabolism, and neurotrophic support. The balance between A1 and A2 phenotypes may influence disease progression.
Astrocyte contributions by disease
In AD, reactive astrocytes surround amyloid plaques and may both limit plaque growth and contribute to neuronal dysfunction through release of inflammatory mediators. In PD, astrocytes accumulate alpha-synuclein and may serve as vectors for pathological protein spread. In ALS, astrocytes fail to support motor neurons and release toxic inflammatory mediators.
Peripheral Immune Cell Involvement
T cells in neurodegeneration
CD4+ and CD8+ T cells infiltrate the brain in AD, PD, and ALS. Regulatory T cells (Tregs) may provide neuroprotective effects, while effector T cells contribute to inflammation. T cell phenotypes differ across diseases:
- PD: CD4+ T cells predominate in early disease; CD8+ cytotoxic T cells increase with progression
- AD: T cell infiltration correlates with plaque burden; memory T cells are expanded
- ALS: T cells are abundant in spinal cord; Tregs are reduced and functionally impaired
B cells and autoantibodies are implicated in neurodegeneration:
- Autoantibodies against neuronal antigens detected in PD and AD
- B cells may act as antigen-presenting cells in CNS
- Intrathecal IgG synthesis is increased in ALS
The Blood-Brain Barrier
BBB dysfunction contributes to neuroinflammation by allowing peripheral immune cell entry:
BBB breakdown in AD
BBB disruption occurs early in AD, with regional variations corresponding to atrophy patterns. Pericyte loss and endothelial dysfunction contribute to leakage of plasma proteins and immune cells.
BBB in PD
Dopaminergic neurons are adjacent to blood vessels in the substantia nigra, making them vulnerable to circulating toxins and inflammatory mediators. BBB breakdown has been documented in PD animal models and patients.
ALS and the BBB
Vascular leakiness in ALS spinal cord allows immune cell infiltration. The extent of BBB disruption correlates with disease severity.
Therapeutic Approaches
Targeting Microglial Activation
CSF1R antagonists
Colony stimulating factor 1 receptor (CSF1R) is required for microglial survival. CSF1R antagonists (e.g., pexidartinib) can reduce microglial numbers in the brain, and this approach is being explored in AD and ALS models.
TREM2 modulators
TREM2 agonists could enhance protective microglial responses in AD. Monoclonal antibodies against TREM2 are in development to enhance signaling while avoiding the complications of full agonism.
CD33 inhibitors
CD33 is an inhibitory receptor that reduces microglial phagocytosis. CD33 genetic variants that reduce expression are associated with lower AD risk, suggesting CD33 inhibition could be therapeutic.
NLRP3 Inflammasome Inhibition
Small molecule inhibitors
MCC950 is a potent NLRP3 inhibitor that has shown efficacy in preclinical models of AD, PD, and ALS. It blocks inflammasome activation and reduces IL-1β production. Other NLRP3 inhibitors in development include dapansutrile (OLT1177) and β-sitosterol.
Natural compounds
Several natural compounds inhibit NLRP3:
- Resveratrol
- Curcumin
- EGCG (epigallocatechin gallate)
- Berberine
Anti-inflammatory Drug Repurposing
Minocycline
This tetracycline antibiotic has anti-inflammatory properties and has been trialed in AD, PD, and ALS. Results have been mixed, possibly due to timing of intervention and patient selection.
NSAIDs
Epidemiological studies suggest reduced AD risk with long-term NSAID use, but clinical trials have not confirmed benefit. The failure may relate to disease stage, NSAID class, and trial design.
Corticosteroids
Brief courses of corticosteroids may provide temporary benefit in ALS, but chronic use causes unacceptable side effects.
Immunomodulatory Strategies
Vaccination approaches
Active immunization against amyloid-beta, tau, and alpha-synuclein is in development. Challenges include:
- Generating antibodies that recognize pathological conformers
- Avoiding autoimmune responses
- Achieving adequate brain penetration
Passive immunization with monoclonal antibodies has shown promise in clearing pathological proteins in trials, but ARIA (amyloid-related imaging abnormalities) remain a concern.
Cytokine blockade
Targeting specific cytokines:
- IL-1β blockade (canakinumab, anakinra)
- TNF-α inhibition (etanercept)
- IL-6 receptor blockade (tocilizumab)
Results have been mixed, suggesting that blanket immune suppression may not be optimal.
Restoration of Immune Balance
Rather than pure immunosuppression, approaches that restore immune homeostasis are being explored:
Microglial repopulation
After CSF1R antagonist treatment, microglia can repopulate the brain with a potentially less inflammatory phenotype.
Regulatory immune cell enhancement
Boosting Tregs or regulatory B cells could restore immune balance without broad immunosuppression.
Metabolic modulation
Microglial metabolic state influences their inflammatory phenotype. Targeting glycolysis or oxidative phosphorylation pathways may shift microglial polarization.
Cross-Links to Related Mechanisms
- [TREM2 Microglial Pathway](/mechanisms/trem2-microglial-pathway)
- [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome)
- [Microglial Priming Pathway](/mechanisms/microglial-priming-pathway)
- [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
- [Complement System Pathway](/mechanisms/complement-system-pathway)
- [Alpha-Synuclein Protein](/proteins/alpha-synuclein)
- [Complement System](/mechanisms/complement-system-neurodegeneration)
- [Neurodegeneration Mechanisms](/mechanisms/genetics)
Key Genes Involved
- TREM2 - Triggering receptor on myeloid cells 2
- CD33 - Sialic acid-binding Ig-like lectin 3
- NLRP3 - NLR family pyrin domain containing 3
- IL1B - Interleukin 1 beta
- TNF - Tumor necrosis factor alpha
- CX3CR1 - CX3C chemokine receptor 1
- CSF1R - Colony stimulating factor 1 receptor
- APOE - [Apolipoprotein E](/proteins/apoe) (affects microglial response)
Replication and Evidence
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
Background
The study of Neuroinflammation Across Ad, Pd, And Als has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research Updates (2024-2026)
- Ahamad S et al. (2026 Mar) [Small-molecule-based activation of Wnt/β-catenin signaling: An underexplored yet promising strategy for neuroprotection.](https://pubmed.ncbi.nlm.nih.gov/41604971/). Bioorg Chem*
- Falahati M et al. (2026 Feb 23) [Microstructural alterations of the amygdala in neurodegenerative and neuroinflammatory disorders: insights from diffusion tensor imaging.](https://pubmed.ncbi.nlm.nih.gov/41720758/). Rev Neurosci*
- Trabulo A et al. (2026 Feb 21) [Mesenchymal Stem Cell-Based Therapies Applied in Neurological Diseases: A Systematic Review.](https://pubmed.ncbi.nlm.nih.gov/41751374/). Biomedicines*
- Ercin N et al. (2026 Feb 16) [Non-canonical cell death in neurodegeneration: emerging mechanisms and therapeutic Frontiers.](https://pubmed.ncbi.nlm.nih.gov/41699331/). [Apoptosis](/entities/apoptosis)*
- Patwekar F et al. (2026 Feb 14) [Marine-Derived bioactive compounds from Aquaculture: Receptor-Mediated neuroprotection in neurodegenerative disorders.](https://pubmed.ncbi.nlm.nih.gov/41698629/). Brain Res*
See Also
- [TREM2 Gene](/genes/trem2)
- [NLRP3 Gene](/genes/nlrp3)
- [IL6 Gene](/genes/il6)
- [CX3CR1 Gene](/genes/cx3cr1)
- [Microglial Activation Mechanisms](/mechanisms/microglial-activation)
- [Astrocyte Reactivity](/cell-types/astrocytes)
- [Complement System in Neurodegeneration](/mechanisms/complement-system-neurodegeneration)
External Links
- [Neuroinflammation in AD, PD, ALS - Nature Reviews Neuroscience](https://www.nature.com/articles/nrn.2017.125)
- [Microglial priming - Brain](https://academic.oup.com/brain/article/140/9/2585/3093443)
- [TREM2 biology - Nature Reviews Immunology](https://www.nature.com/articles/nri.2016.74)
Cross-Disease Neuroinflammation Pathway
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-neuroinflammation-ad-pd-als |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-51aa423d8579 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-neuroinflammation-ad-pd-als'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-neuroinflammation-ad-pd-als?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[neuroinflammation-ad-pd-als](http://scidex.ai/artifact/wiki-mechanisms-neuroinflammation-ad-pd-als)
http://scidex.ai/artifact/wiki-mechanisms-neuroinflammation-ad-pd-als